Statement of Changes in Beneficial Ownership (4)
09 Setembro 2022 - 5:03PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Zukiwski Alexander A |
2. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc.
[
CASI
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP and Chief Medical Officer |
(Last)
(First)
(Middle)
CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/7/2022 |
(Street)
ROCKVILLE, MD 20850
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Buy) | $15.2 (2) | 9/7/2022 | | A | | 3000 (2) | | (1) | 5/25/2031 | Common Stock | 3000 (2) | $0 | 3000 (2) | D | |
Explanation of Responses: |
(1) | On May 25, 2021, subject to approval at the June 15, 2021 shareholders meeting, the reporting person was granted these stock options that vest upon achievement of certain performance based conditions. The performance based condition was satisfied on September 7, 2022, resulting in vesting of the options. |
(2) | On June 1, 2022, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split"). The number of stock options and the exercise price reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Zukiwski Alexander A CASI PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE, SUITE 300 ROCKVILLE, MD 20850 |
|
| EVP and Chief Medical Officer |
|
Signatures
|
/s/Alexander A. Zukiwski | | 9/9/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
CASI Pharmaceuticals (NASDAQ:CASI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
CASI Pharmaceuticals (NASDAQ:CASI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024